Editorial: Hot topics in diabetes and steatotic liver disease
Non-alcoholic fatty liver disease (NAFLD), currently reframed as metabolic dysfunction-associated steatotic liver disease (MASLD), is one of the most prevalent...
steatotic
Multi-Modal AI Advances Steatotic Liver Disease Screening
In a groundbreaking advance that promises to revolutionize the landscape of liver disease diagnosis and management, researchers have developed a...
Screening and diagnosis of metabolic dysfunction-associated steatotic liver disease in children within public healthcare
Patients and study designThe study was conducted at the Tampere Center for Child, Adolescent, and Maternal Health Research, Tampere University,...
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment...
